Identification of the Best Prognostic Marker Among Immunonutritional Parameters Using Serum C-Reactive Protein and Albumin in Non-Small Cell Lung Cancer.
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
04
06
2020
accepted:
19
09
2020
pubmed:
22
10
2020
medline:
18
5
2021
entrez:
21
10
2020
Statut:
ppublish
Résumé
Three immune-nutritional parameters exist for malignant tumors using serum C-reactive protein (CRP) and albumin: the Glasgow prognostic score (GPS), the modified GPS (mGPS), and the CRP-albumin ratio (CAR). However, it remains unclear which of the three parameters is the most predictive of prognosis. Therefore, this study compared the clinical and prognostic significance of these parameters for non-small cell carcinoma (NSCLC). The study retrospectively enrolled 596 NSCLC patients who underwent surgical resection at the authors' institution from January 2010 to December 2015 and investigated the clinicopathologic significance of GPS, mGPS, and CAR. The optimal cutoff value for CAR was determined by a receiver operating curve (ROC). The median age of the patients was 69 years. Lymph node metastases were identified in 99 patients, and 455 patients had a diagnosis of stage 1 disease. The positivity for GPS was 7.6%, and that of mGPS (score, 1 or 2) was 12.2%. Of the 596 patients, 480 patients (80.5%) were classified in the high CAR group. In univariate survival analyses, all three parameters were associated significantly with postoperative survival. The multivariate analyses showed CAR to be an independent prognostic factor. Additionally, survival analyses of the stage 1 subgroup were performed because CAR was higher for patients with an advanced stage of disease or lymph node metastases. In these subgroup analyses, CAR also was an independent prognostic factor. As the most prognostic index, CAR may be useful among the immunonutritional parameters using CRP and albumin for resected NSCLC.
Sections du résumé
BACKGROUND
BACKGROUND
Three immune-nutritional parameters exist for malignant tumors using serum C-reactive protein (CRP) and albumin: the Glasgow prognostic score (GPS), the modified GPS (mGPS), and the CRP-albumin ratio (CAR). However, it remains unclear which of the three parameters is the most predictive of prognosis. Therefore, this study compared the clinical and prognostic significance of these parameters for non-small cell carcinoma (NSCLC).
METHODS
METHODS
The study retrospectively enrolled 596 NSCLC patients who underwent surgical resection at the authors' institution from January 2010 to December 2015 and investigated the clinicopathologic significance of GPS, mGPS, and CAR. The optimal cutoff value for CAR was determined by a receiver operating curve (ROC).
RESULTS
RESULTS
The median age of the patients was 69 years. Lymph node metastases were identified in 99 patients, and 455 patients had a diagnosis of stage 1 disease. The positivity for GPS was 7.6%, and that of mGPS (score, 1 or 2) was 12.2%. Of the 596 patients, 480 patients (80.5%) were classified in the high CAR group. In univariate survival analyses, all three parameters were associated significantly with postoperative survival. The multivariate analyses showed CAR to be an independent prognostic factor. Additionally, survival analyses of the stage 1 subgroup were performed because CAR was higher for patients with an advanced stage of disease or lymph node metastases. In these subgroup analyses, CAR also was an independent prognostic factor.
CONCLUSION
CONCLUSIONS
As the most prognostic index, CAR may be useful among the immunonutritional parameters using CRP and albumin for resected NSCLC.
Identifiants
pubmed: 33084992
doi: 10.1245/s10434-020-09230-x
pii: 10.1245/s10434-020-09230-x
doi:
Substances chimiques
Albumins
0
C-Reactive Protein
9007-41-4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3046-3054Références
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424.
Williams BA, Sugimura H, Endo C, et al. Predicting postrecurrence survival among completely resected nonsmall-cell lung cancer patients. Ann Thorac Surg. 2006;81:1021–7.
pubmed: 16488713
doi: 10.1016/j.athoracsur.2005.09.020
Sugimura H, Nichols FC, Yang P, et al. Survival after recurrent non-small cell lung cancer after complete pulmonary resection. Ann Thorac Surg. 2007;83:409–17. (discussioin 417–408)
Sonobe M, Yamada T, Sato M, et al. Identification of subsets of patients with favorable prognosis after recurrence in completely resected non-small cell lung cancer. Ann Surg Oncol. 2014;21:2546–54.
pubmed: 24633668
doi: 10.1245/s10434-014-3630-9
Taylor MD, Nagji AS, Bhamidipati CM, et al. Tumor recurrence after complete resection for non-small cell lung cancer. Ann Thorac Surg. 2012;93:1813–20. (discussion 1820–1811)
Mizuno T, Arimura T, Kuroda H, Sakakura N, Yatabe Y, Sakao Y. Current outcomes of postrecurrence survival in patients after resection of non-small cell lung cancer. J Thorac Dis. 2018;10:1788–96.
pubmed: 29707333
pmcid: 5906349
doi: 10.21037/jtd.2018.01.148
Matsubara T, Takada K, Azuma K, et al. A clinicopathological and prognostic analysis of PD-L2 expression in surgically resected primary lung squamous cell carcinoma. Ann Surg Oncol. 2019;26:1925–33.
pubmed: 30815803
doi: 10.1245/s10434-019-07257-3
Mahmoud FA, Rivera NI. The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Rep. 2002;4:250–5.
pubmed: 11937016
doi: 10.1007/s11912-002-0023-1
Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of Malignant Tumours. J Thorac Oncol. 2007;2:706–14.
pubmed: 17762336
doi: 10.1097/JTO.0b013e31812f3c1a
Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ. Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small cell lung cancer. Br J Cancer. 2004;90:1704–6.
pubmed: 15150622
pmcid: 2409737
doi: 10.1038/sj.bjc.6601789
Inoue Y, Iwata T, Okugawa Y, et al. Prognostic significance of a systemic inflammatory response in patients undergoing multimodality therapy for advanced colorectal cancer. Oncology. 2013;84:100–7.
pubmed: 23147449
doi: 10.1159/000343822
Miyazaki T, Yamasaki N, Tsuchiya T, et al. Ratio of C-reactive protein to albumin is a prognostic factor for operable non-small cell lung cancer in elderly patients. Surg Today. 2017;47:836–43.
pubmed: 27853867
doi: 10.1007/s00595-016-1448-8
Zhang F, Ying L, Jin J, et al. The C-reactive protein/albumin ratio predicts long-term outcomes of patients with operable non-small cell lung cancer. Oncotarget. 2017;8:8835–42.
pubmed: 27823974
doi: 10.18632/oncotarget.13053
Kinoshita A, Onoda H, Imai N, et al. The C-reactive protein/albumin ratio, a novel inflammation-based prognostic score, predicts outcomes in patients with hepatocellular carcinoma. Ann Surg Oncol. 2015;22:803–10.
pubmed: 25190127
doi: 10.1245/s10434-014-4048-0
Yamauchi Y, Safi S, Muley T, et al. C-reactive protein-albumin ratio is an independent prognostic predictor of tumor recurrence in stage IIIA-N2 lung adenocarcinoma patients. Lung Cancer. 2017;114:62–7.
pubmed: 29173768
doi: 10.1016/j.lungcan.2017.11.002
Ni XF, Wu J, Ji M, et al. Effect of C-reactive protein/albumin ratio on prognosis in advanced non-small cell lung cancer. Asia-Pacific J Clin Oncol. 2018;14:402–9.
doi: 10.1111/ajco.13055
Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860–7.
pubmed: 12490959
pmcid: 2803035
doi: 10.1038/nature01322
Pikarsky E, Porat RM, Stein I, et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature. 2004;431:461–6.
pubmed: 15329734
doi: 10.1038/nature02924
Murata M. Inflammation and cancer. Environment Health Prevent Med. 2018;23:50.
doi: 10.1186/s12199-018-0740-1
Guthrie GJ, Roxburgh CS, Horgan PG, McMillan DC. Does interleukin-6 link explain the link between tumour necrosis, local and systemic inflammatory responses, and outcome in patients with colorectal cancer? Cancer Treat Rev. 2013;39:89–96.
pubmed: 22858249
doi: 10.1016/j.ctrv.2012.07.003
Yeung YT, Aziz F, Guerrero-Castilla A, Arguelles S. Signaling pathways in inflammation and anti-inflammatory therapies. Curr Pharmaceut Design. 2018;24:1449–84.
doi: 10.2174/1381612824666180327165604
Volanakis JE. Human C-reactive protein: expression, structure, and function. Mol Immunol. 2001;38:189–97.
pubmed: 11532280
doi: 10.1016/S0161-5890(01)00042-6
Lee JG, Cho BC, Bae MK, et al. Preoperative C-reactive protein levels are associated with tumor size and lymphovascular invasion in resected non-small cell lung cancer. Lung Cancer. 2009;63:106–10.
pubmed: 18513823
doi: 10.1016/j.lungcan.2008.04.011
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.
pubmed: 21376230
doi: 10.1016/j.cell.2011.02.013
O’Loughlin J, Lambert M, Karp I, et al. Association between cigarette smoking and C-reactive protein in a representative, population-based sample of adolescents. Nicotine Tobacco Res. 2008;10:525–32.
doi: 10.1080/14622200801901997
Higgins ST, Kurti AN, Redner R, et al. A literature review on prevalence of gender differences and intersections with other vulnerabilities to tobacco use in the United States, 2004–2014. Prevent Med. 2015;80:89–100.
doi: 10.1016/j.ypmed.2015.06.009
Suarez-Carmona M, Lesage J, Cataldo D, Gilles C. EMT and inflammation: inseparable actors of cancer progression. Mol Oncol. 2017;11:805–23.
pubmed: 28599100
pmcid: 5496491
doi: 10.1002/1878-0261.12095
Wang L, Cao L, Wang H, et al. Cancer-associated fibroblasts enhance metastatic potential of lung cancer cells through IL-6/STAT3-signaling pathway. Oncotarget. 2017;8:76116–28.
pubmed: 29100297
pmcid: 5652691
doi: 10.18632/oncotarget.18814
Matsubara T, Tagawa T, Takada K, et al. Clinical and prognostic significance of the epithelial-mesenchymal transition in stage IA lung adenocarcinoma: a propensity score-matched analysis. Clin Lung Cancer. 2019;20(4):e504–13.